Back to search

Peptide record

TPDB41065

FKRLA Anticancer standard
17 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB41065
FKRLA
Anticancer
Cancer-related peptides
ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 Peptipedia SATPdb iACP-DRLF pep-lab
standard
No
A 17-aa standard natural anticancer peptide sequence curated from ACP740 _ACP240, AntiCP 2.0, CancerPPD 2.0, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
FKRLAKIKVLRLAKIKR-NH2
Physicochemical Analysis
C98H181N31O18
NDCEQGHMPSTWY
K
2081.71
12.72
8
0
9
+8
3.68
-0.118
143.53
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
0
Residue Composition
number
2
A
3
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
2
I
3
L
5
K
0
M
1
F
0
P
0
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 2 R: 3 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 2 L: 3 K: 5 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
17
C98H181N31O18
2081.71
12.72
+8
3.68
-0.118
Amidation
L
Linear
Free
Anticancer
FLAK peptides
Evidence Records 6 records
Evidence 1 Activity

Activity

LD50
LD50 =106 µg/ml
Anticancer
106 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

LD50
LD50 =185 µg/ml
Anticancer
185 µg/mL

Target

Colon Cancer
SW-480
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 3 Activity

Activity

LD50
LD50 =110 µg/ml
Anticancer
110 µg/mL

Target

Skin Cancer
BMKC
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 4 Activity

Activity

LD50
LD50 =93 µg/ml
Anticancer
93 µg/mL

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 5 Activity

Activity

LD50
LD50 =340 µg/ml
Anticancer
340 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 6 Activity

Activity

LD50
LD50 = >1000 µg/ml
Anticancer
>1000 µg/mL

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2